首页 | 本学科首页   官方微博 | 高级检索  
检索        

内科综合治疗HBV-ACLF患者的临床特点及转归
引用本文:高朋彬,郑欢伟,赵晓彦,王德华,秦浩,孟明辉,张建集,闫双缓.内科综合治疗HBV-ACLF患者的临床特点及转归[J].肝脏,2020(4):375-378.
作者姓名:高朋彬  郑欢伟  赵晓彦  王德华  秦浩  孟明辉  张建集  闫双缓
作者单位:石家庄市第五医院感染科;石家庄市第五医院肿瘤内科;石家庄市第五医院重症医学科;河北医科大学附属第一医院儿科
基金项目:肝硬化基础乙肝相关慢加急肝衰竭非肝移植内科治疗临床转归石家庄市科学技术研究与发展计划项目(171461873)。
摘    要:目的了解HBV-ACLF内科治疗患者的临床特点及预后。方法回顾性分析140例接受内科综合治疗的HBV-ACLF患者临床资料,根据治疗效果分为有效组和无效组。比较两组患者临床特点。结果内科综合治疗有效98例,无效42例,死亡23例。有效组肝硬化病史、肝性脑病、消化道出血及肝肾综合征发生率均低于无效组(P<0.05)。Logistic多因素分析显示,肝性脑病(OR=1.869,95%CI=1.073~3.256)、消化道出血(OR=3.478,95%CI=1.621~7.462)、肝肾综合征(OR=4.141,95%CI=1.031~5.091)、INR(OR=3.081,95%CI=1.497~6.341)、Scr(OR=2.817,95%CI=1.629~4.871)和MELD评分(OR=1.305,95%CI=1.194~1.426)是影响其疗效的独立因素(P<0.05)。结论HBV-ACLF内科综合疗效肯定,恩替卡韦联合糖皮质激素有助于提高疗效,而对于合并并发症、肝功能下降及MELD评分升高者,内科治疗效果较差。

关 键 词:HBV-ACLF  临床特点  预后转归

The clinical characteristics and prognosis of patients with HBV-ACLF treated by internal medicine
GAO Peng-bin,ZHENG Huan-wei,ZHAO Xiao-yan,WANG De-hua,QIN Hao,MENG Ming-hui,ZHANG Jian-ji,YAN Shuang-huan.The clinical characteristics and prognosis of patients with HBV-ACLF treated by internal medicine[J].Chinese Hepatology,2020(4):375-378.
Authors:GAO Peng-bin  ZHENG Huan-wei  ZHAO Xiao-yan  WANG De-hua  QIN Hao  MENG Ming-hui  ZHANG Jian-ji  YAN Shuang-huan
Institution:(Department of infection,the fifth hospital in Shijiazhuang,Hebei,Shijiazhuang,Hebei 050000;Department of oncology,the fifth hospital in Shijiazhuang,Hebei,Shijiazhuang,Hebei 050000;Department of critical medicine,the fifth hospital of Shijiazhuang,Hebei,Shijiazhuang,Hebei 050000;Department of Pediatrics,the First Affiliated Hospital of Hebei Medical University,Shijiazhuang,Hebei 050000)
Abstract:Objective To study the clinical characteristics and prognosis of patients with HBV-related acute-on-chronic liver failure(HBV-ACLF)treated by internal medicine.Methods The clinical data of 140 patients with HBV-ACLF who received comprehensive treatment of internal medicine in our hospital were retrospectively analyzed,the patients were divided into effective group and ineffective group,which accorded to the therapeutic effect.The clinical characteristics of the two groups were compared.Results The medical comprehensive treatment was effective in 98 cases,the effective rate was 70.00%,the ineffective was 42 cases and the ineffective rate was 30%.Among them,23 cases died and the mortality rate was 16.43%.The incidence of cirrhosis,hepatic encephalopathy,gastrointestinal bleeding and hepatorenal syndrome in the effective group were lower than that in the ineffective group(P<0.05).The Logistic multivariate analysis showed that the complications such as hepatic encephalopathy(OR=1.869,95%CI=1.073~3.256),gastrointestinal bleeding(OR=3.478,95%CI=1.621~7.462),hepatorenal syndrome(OR=4.141,95%CI=1.031~5.091)and INR(OR=3.081,95%CI=1.497~6.341),Scr(OR=2.817,95%CI=1.629~4.871)and MELD scores(OR=1.305,95%CI=1.194~1.426)were independent factors which affected the efficacy(P<0.05).Conclusion The comprehensive curative effect of HBV-ACLF is affirmative.The entecavir combined with glucocorticoid is helpful to improve the curative effect.The patients who decreased liver function and elevated MELD score,the therapeutic effect of internal medicine for those with complications is worse.
Keywords:HBV-ACLF  Clinical features  Prognosis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号